pharmaphorum

OCTOBER 26, 2021

We certainly have a problem with national-level procurement policies that put almost no value on generic medicines … that approach needs to change. Access is dependent on securing a robust medicines supply chain, meaning companies need to invest in European manufacturing facilities.

Generic Medicine 122

Generic Medicine Biosimilars 122

pharmaphorum

JULY 4, 2022

Hughes will take charge of an R&D unit spending around $1 billion on R&D across Teva’s generics, biosimilars and speciality medicines categories – two-thirds spent in the US – at 26 R&D sites worldwide, employing around 3,500 scientists.

Generic Medicine 52

Generic Medicine Biosimilars 52

Pharmaceutical Technology

FEBRUARY 28, 2023

The company offers generic medicines and biosimilars through Sandoz. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others.

Generic Medicine 40

Generic Medicine Biosimilars Immunity Immunization 40

European Pharmaceutical Review

JULY 29, 2024

Subject to regulatory approval by the European Commission, Yuvanci ® would be the only single tablet combination therapy in Europe for pulmonary arterial hypertension, Johnson & Johnson Innovative Medicine shared. Tuznue (trastuzumab) for breast and gastric cancer.

Generic Medicine 52

Generic Medicine Biosimilars 52

Pharmaceutical Technology

FEBRUARY 28, 2023

The company offers generic medicines and biosimilars through Sandoz. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others.

Generic Medicine 40

Generic Medicine Immunity Immunization Biosimilars 40

Pharmaceutical Technology

FEBRUARY 28, 2023

The company offers generic medicines and biosimilars through Sandoz. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others.

Generic Medicine 40

Generic Medicine Immunity Immunization Biosimilars 40

Quality Matters

JANUARY 23, 2023

Leveraging insights from data on USP standards distribution and usage at more than 22,000 locations worldwide and 40+ external data sets, USP launched the Medicine Supply Map in 2021 to provide an early-warning capability for supply chain vulnerabilities. Such products include small molecule medicines, biologics and biosimilars.

Generic Medicine 52

Generic Medicine Pharmaceutical Manufacturing Biosimilars Communication 52

Pharma in Brief

JUNE 21, 2020

Medicines with an annual treatment cost >150% of GDP/capita or maximum expected market size >$50 M will be classified as Category I, except biosimilars and generics. Medicines falling below these thresholds, as well as biosimilars and generics, will be classified as Category II.

Biosimilars 40

Biosimilars Generic Medicine Dosage Documentation 40

Pharmaceutical Technology

FEBRUARY 18, 2023

The company offers generic medicines and biosimilars through Sandoz. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others.

Diabetes 40

Diabetes Generic Medicine Biosimilars Immunity 40

Express Pharma

JULY 3, 2023

For decades, Waters has been a trusted partner to many pharma and generics companies operating in India, particularly for small molecule QA/QC. India is known as the ‘Pharmacy of the World’, as the generic medicine supplier for over 200 countries, both developed and emerging markets. How poised are you to leverage them?

Biosimilars 95

Biosimilars Drug Development Generic Medicine Diabetes 95

European Pharmaceutical Review

APRIL 30, 2024

CHMP biosimilar recommendations A positive opinion for Tofidence (tocilizumab) was adopted by the committee, indicated for rheumatoid arthritis, COVID-19, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. This covers paediatric plaque psoriasis, psoriatic arthritis and Crohn’s disease.

Biosimilars 98

Biosimilars Generic Medicine Chemotherapy Hospitals 98

European Pharmaceutical Review

JULY 1, 2024

The committee gave a positive opinion for the biosimilar Steqeyma (ustekinumab). Additionally, approval was recommended two generic medicines: Enzalutamide Viatris (enzalutamide) to treat prostate cancer, and Nilotinib Accord (nilotinib) was also recommended to treat Philadelphia chromosome positive chronic myelogenous leukaemia.

Generic Medicine 106

Generic Medicine Vaccines Biosimilars 106

European Pharmaceutical Review

FEBRUARY 26, 2024

Other positive opinions by the CHMP Zynyz* (retifanlimab) as a treatment for Merkel cell carcinoma, a type of skin cancer Pyzchiva (ustekinumab), a biosimilar used to treat plaque psoriasis The generic medicine Apremilast Accord (apremilast), for psoriatic arthritis, psoriasis and Behçet’s disease, a rare type of inflammatory disease Generic medicine (..)

Generic Medicine 98

Generic Medicine Vaccines Pharmaceutical Companies Pharmaceutical Companies 98

Quality Matters

APRIL 20, 2023

Launched in 2021 and composed of more than 250 million data points spanning 92% of generic medicines approved in the U.S.,

Biosimilars 52

Biosimilars Labelling Vaccines Generic Medicine 52

European Pharmaceutical Review

APRIL 3, 2023

The CHMP adopted a positive opinion for Epysqli (eculizumab), a biosimilar medicine for paroxysmal nocturnal haemoglobinuria. Pedmarqsi is indicated in patients from one month up to 18 years old with localised, non-metastatic, solid tumours.

Vaccines 98

Vaccines Chemotherapy Generic Medicine Biosimilars 98

European Pharmaceutical Review

NOVEMBER 14, 2022

Four medicines recommended for approval in the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP)’s latest meeting included a biosimilar for osteoporosis and a novel COVID-19 vaccine.

Vaccines 98

Vaccines Biosimilars Generic Medicine 98

European Pharmaceutical Review

SEPTEMBER 21, 2022

Biosimilar medicine Ximluci (ranibizumab) for the treatment of neovascular age-related macular degeneration, a progressive retinal macular disease, causing gradual vision impairment, mainly in the elderly population. Teriparatide SUN (teriparatide) for the treatment of osteoporosis in adults.

Vaccines 98

Vaccines Generic Medicine Biosimilars 98

Express Pharma

MARCH 3, 2025

According to him, Passing the PILLS Act is a necessary first step to reverse this trend, restore American pharmaceutical production, create high-quality jobs, and protect national security by ensuring a safe, reliable domestic supply of high-quality generic medicines, antibiotics, and other essential drugs.” Sounds familiar?

Generic Medicine 94

Generic Medicine Biosimilars 94

European Pharmaceutical Review

FEBRUARY 3, 2025

Biosimilars given a positive opinion Dyrupeg (pegfilgrastim) to reduce the duration of neutropenia and help prevent febrile neutropenia following chemotherapy. New vaccine Vimkunya (chikungunya vaccine (recombinant, adsorbed)) was also recommended for individuals 12 years old and adults to prevent disease caused by the Chikungunya virus.

Vaccines 52

Vaccines Generic Medicine Chemotherapy Biosimilars 52